| Today’s Big NewsJun 14, 2024 |
| By James Waldron Investors celebrating the summer resurgence of biotech IPOs might want to put the champagne back on ice, after Telix Pharmaceuticals made the last-minute decision to pull its own Nasdaq listing plans. |
|
|
|
By Annalee Armstrong Cabaletta Bio’s shares tumbled 13% Friday morning as the biotech shared just a crumb of data from two patients in an autoimmune CAR T trial that hinted at remission. |
By Gabrielle Masson,Andrea Park,Fraiser Kansteiner Longtime J&J exec Willaim Hait, M.D., Ph.D., is set to retire this fall after a 17-year run with the Big Pharma. |
Sponsored by Montgomery County Economic Development Corporation Drive or take the metro in any direction within Montgomery County, Maryland, and you'll come across a life science company responsible for a major innovation. |
|
Tuesday, June 25, 2024 | 11am ET / 8am PT Expanded Access Programs can help deliver life-saving access to critical medications. Join us for a deep dive into the benefits of EAPs in Europe. Learn how to leverage for achieving faster access to the European market, facilitating successful commercialization, and navigating the array of regulations and guidelines. Register now. 
|
|
By Nick Paul Taylor Innovent Biologics' bispecific immuno-oncology candidate IBI363 has been linked to a 100% response rate in a small cohort of Chinese lung cancer patients. |
By Gabrielle Masson J.P. Morgan Private Capital has closed an inaugural life sciences fund of more than $500 million, cash that will go toward a wide range of private biotechs and build value for existing portfolio companies. |
By James Waldron enGene is halting work on a cystic fibrosis program to focus resources on moving its lead candidate further into bladder cancer. |
By Gabrielle Masson,Annalee Armstrong,Max Bayer Welcome to Fierce Biotech's Fundraising Tracker, 2024's version. |
By Ayla Ellison,Gabrielle Masson,Angus Liu In this week's episode of "The Top Line," journalists from Fierce Biotech and Fierce Pharma discuss the most talked-about data drops at ASCO and share on-the-ground details, including their experience with Gilead’s virtual reality Trodelvy ride. |
By Angus Liu Pfizer's oncology commercial chief Suneet Varma told Fierce Pharma that the division's plan to have eight blockbusters by 2030 will have contribution from each of its four focused therapeutic areas: breast, genitourinary, hematology and thoracic cancers. |
By Conor Hale Invizius' H-Guard priming solution coats the inside of a dialysis machine to cloak the hardware from the blood's heightened immune system response. |
By Heather Landi According to the DOJ, Done's CEO and clinical president allegedly arranged the prescription of 40 million Adderall pills as well as other stimulants, generating more than $100 million in revenue. |
By Angus Liu A Bristol Myers Squibb drug has got an FDA approval to treat tumors with a specific biomarker regardless of their locations in the body, and it's facing two competitors. |
By Angus Liu Through a deal with a Chinese biotech, AbbVie is the latest Big Pharma to bet on TL1A in immunology. A former Takeda employee has pleaded guilty to scamming the Japanese drugmaker. Kyowa Kirin will invest up to $530 million in a biologics plant in North Carolina. And more. |
Fierce podcasts Don’t miss an episode |
| In this week's episode of "The Top Line," journalists from Fierce Biotech and Fierce Pharma discuss the most talked-about data drops at ASCO and share on-the-ground details, including their experience with Gilead’s virtual reality Trodelvy ride. |
|
|---|
|
|
|
July 8-9, 2024 | Jersey City, NJ Hear the latest industry trends from leaders in the field, and developed with input from our esteemed advisory board, to ensure you have a sound plan for your company, brands, and yourself.
Save $200 when you Register Today! +(1).png)
|
|
Webinar Watch our on-demand webinar video to learn more about the challenges in pDNA manufacturing for gene and cell therapy and how to resolve many of these barriers by partnering with our experts through the adoption of vital manufacturing technologies and strategies. Sponsored by: Aldevron |
Whitepaper New molecular formats are gaining momentum in today’s market. Characterizing these products and developing robust manufacturing processes can help to usher them to market and provide new treatment options for diseases which are currently challenging to treat. Read this white paper to learn more. Presented by: Lonza |
Whitepaper This detailed case study shows how Fresenius Medical Care achieved 25 times faster insights to help kidney disease patients, launching the world’s largest global database of dialysis care with fully anonymized patient data. Sponsored by: Privacy Analytics, an IQVIA company |
Whitepaper This paper outlines the challenges, pitfalls, & solutions associated with adding rare disease therapies to a biopharma company’s portfolio. Sponsored by: AIM, the strategic leader in life science supply chains |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
+114x60.png)
